Background
HIV-2 is less pathogenic than HIV-1, with lower levels of plasma HIV-2 RNA levels and slower rates of CD4 lymphopenia. Cellular immune activation (CD8+DR+, CD8+CD38+DR+) is common in untreated persions with HIV-2 (PWH2) and has been reported to be associated with levels of viremia or cell-associated HIV-2 DNA. Effects of anti-retroviral therapy (ART) on immune activation have not been extensively studied. To investigate the effects of antiretroviral therapy on immune activation, we quantified levels of lymphocyte cell subsets in participants with HIV-2 prior to and following ART initiation otherwise healthy controls.
Methods
Plasma and peripheral blood mononuclear cells (PBMC) were obtained from individuals infected with HIV-2 (N=5) or uninfected, otherwise healthy controls matched for age, sex, and race. PBMC underwent immunophenotyping (FACS) for CD8CD38 and CD8+CD38+DR+ Longitudinal samples from PWH were obtained prior to (n=21) and following ART initiation (n=15). In PWH2, proviral DNA was assayed in 2.4-6 million PBMC in 4/5 PWH2.Parametric statistics were used to analyze data.
Results
PWH2 (N=5, 1 woman) and matched controls (N=33) were studied. As expected. pretherapy levels of CD8+38+DR+ and CD8+DR+ were significantly higher in PWH2; mean CD8+CD38+DR+ PWH2 (42.2%) vs. controls (15%; p=2e-5); CD8+DR+ (62.4% vs. 27.9% p= 8e-6). After >3 y on ART, levels of CD8 subsets were still significantly elevated (p=0.005, p=0.0002 respectively) indicating immune activation persisted . Proviral DNA levels were not detected in 2/3 individuals undergoing ART; levels in one PWH2 were low (7 c/million PBMC). Interestingly, in one individual, HIV-2 RNA and proviral DNA could not be detected pretherapy, despite significant CD8 subset elevations.
Conclusions
Elevated immune activation persists despite long-term ART, and low or undetectable levels of HIV-2 DNA. In PWH2. Viral sources of immune activation are likely based in tissues, not blood.